CARTITUDE-5
Tests CAR-T as frontline consolidation instead of ongoing lenalidomide in patients not having a transplant.
Together with CARTITUDE-6 (EMagine, cilta-cel vs autologous transplant after Dara-VRd in transplant-eligible patients) it asks whether one CAR-T infusion can replace transplant or maintenance. No results as of mid-2026.
Pages like this
not linked directly; found by shared links- TrialCARTITUDE-4
Shares One CAR-T infusion instead of autologous transplant, CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Ciltacabtagene autoleucel, Multiple myeloma.
- CompanyLegend Biotech
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Ciltacabtagene autoleucel, Multiple myeloma.
- TrialCARTITUDE-1
- PersonPaul G. Richardson
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma.
- ProductPomalidomide
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Multiple myeloma.
- PersonJohn F. DiPersio
Shares Autologous stem cell transplant (high-dose therapy), Multiple myeloma.
- Key paperCARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma
Shares CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy, Ciltacabtagene autoleucel, Multiple myeloma.
- InstitutionIUCT Oncopole – Institut Universitaire du Cancer de Toulouse